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Ca2+ sensitivity of smooth muscle (SM) contraction is determined by CPI-17, an inhibitor 
protein for myosin light chain phosphatase (MLCP). CPI-17 is highly expressed in mature SM 
cells, but the expression level varies under pathological conditions. Here, we determined the 
expression of CPI-17 in embryonic SM tissues and arterial neointimal lesions using 
immunohistochemistry. As seen in adult animals, the predominant expression of CPI-17 was 
detected at SM tissues on mouse embryonic sections, whereas MLCP was ubiquitously 
expressed. Compared with SM α-actin, CPI-17 expression doubled in arterial SM from 
embryonic day E10 to E14. Like SM α-actin and other SM marker proteins, CPI-17 was 
expressed in embryonic heart, and the expression was down-regulated at E17. In adult rat, CPI-
17 expression level was reduced to 30 % in the neointima of injured rat aorta, compared with 
the SM layers, whereas the expression of MLCP was unchanged in both regions. Unlike other 
SM proteins, CPI-17 was detected at non-SM organs in the mouse embryo, such as embryonic 
neurons and epithelium. Thus, CPI-17 expression is reversibly controlled in response to the 
phenotype transition of SM cells that restricts the signal to differentiated SM cells and particular 
cell types. 
Kim et al. Histochem Cell Biol.   




Vascular smooth muscle (SM) contraction is triggered by the phosphorylation of myosin 
light chain (MLC), which is controlled through two major signaling pathways: the activation of 
MLC kinase (MLCK) and the inhibition of MLC phosphatase (MLCP). The inhibition of MLCP 
occurs upon G-protein activation in response to agonist stimuli.  MLCP activity is increased in 
response to nitric oxide production causing myosin dephosphorylation and SM relaxation. Thus, 
MLCP activity plays an important role in the regulation of both SM contraction and relaxation. 
MLCP is a heterotrimeric enzyme, consisting of a delta isoform of protein phosphatase-1 
catalytic subunit (PP1∂), a myosin targeting subunit (MYPT1), and an accessory M21 subunit 
(Hartshorne et al. 2004). MYPT1 tethers PP1∂ to myosin filaments and determines the substrate 
specificity (Hartshorne et al. 2004). MLCP activity is suppressed via the bi-phasic 
phosphorylation of MYPT1 and an inhibitor protein for MLCP, CPI-17 (Dimopoulos et al. 2007). 
CPI-17, a 17-kDa cytosolic protein, potently and selectively inhibits MLCP in SM when it is 
phosphorylated at Thr38 (Eto et al. 1995; Eto et al. 2004). The phosphorylation of CPI-17 occurs 
in response to agonist stimulation, and it reversibly declines in response to NO/cGMP (Etter et 
al. 2001; Dimopoulos et al. 2007), suggesting a critical role of CPI-17 in the regulation of MLC 
phosphorylation and SM contraction. 
In adult animals, MYPT1 is ubiquitously expressed (Okubo et al. 1994), whereas CPI-17 
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is predominantly expressed at SM tissues and brain in adult rat (Woodsome et al. 2001; Eto et 
al. 2002). Among SM tissues, CPI-17 expression is higher in tonic muscles, such as arteries, but 
lower in phasic muscles, such as ileum and urinary bladder. Importantly, the expression level of 
CPI-17 in each tissue correlates with the extent of PKC-induced contraction (Woodsome et al. 
2001). Furthermore, arterial SM from adult farm chicken expresses undetectable level of 
endogenous CPI-17 and produces a negligible level of the force in response to G-protein 
activation (Kitazawa et al. 2004). Thus, the expression level of CPI-17 is a critical determinant of 
the extent of the myosin phosphorylation and SM contraction induced through G-protein-
mediated signals.  
Accumulating evidence shows that up- and down-regulation of CPI-17 occurs under 
pathological conditions, such as inflammation, asthma, diabetes, and hypoxia, resulting in 
abnormal SM contraction (Ohama et al. 2003; Dakshinamurti et al. 2005; Sakai et al. 2005; 
Chang et al. 2006). It is known that these pathological as well as physiological factors, such as 
an increase in blood flow, affect the differentiation state of SM cells causing the reversible 
transition between a contractile and proliferative phenotype (Owens et al. 2004). A group of 
transcriptional cofactors, myocardin and other family members, Myocardin Related Transcription 
Factors (MRTFs), play an important role in orchestrating the gene expression of SM marker 
proteins, including SM α-actin, SM myosin heavy chain (MHC), SM22 and calponin, through 
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serum-response transcription factor (Wang and Olson. 2004). However, it is not yet known 
whether the phenotype transition of SM cells alters the expression of CPI-17.  In the present 
study, we examined CPI-17 expression at three different stages during mouse embryo 
development and at de-differentiated neointimal lesions at the injured site of rat aorta. The 
results revealed SM differentiation-dependent regulation of CPI-17 expression, as well as the 
novel expression of CPI-17 in embryonic epithelium. This provides evidence that the regulation 
of MLCP activity is programmed at each locus through the transcription of CPI-17.  
Kim et al. Histochem Cell Biol.   
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Materials and Methods 
Mouse embryo tissue sections: Sagittal sections of paraffin embedded mouse whole embryo 
at embryonic day 10, 14, and 17 (E10, 14, 17) were purchased from Zyagen (Zyagen, San 
Diego, CA, USA).  
Aorta injury model: Aorta injury was performed in Sprague Dawley rats (7 to 9 w) using a 
balloon catheter introduced through the carotid artery. Vessels were harvested 14 days later, as 
described previously (Jin et al. 2007). The animal protocol was approved by ICUC at University 
of Virginia. 
Immunohistochemistry of sections of mouse embryo and aorta: All processes were done at 
room temperature. Deparaffinization and rehydration were performed by successive immersion 
for 10 min in each of the following solutions:  xylene, ethanol (100%, 90%, 80%, 70%), and 
distilled water. After a 5-min permeabilization 0.1% Triton X-100 in PBS and then 1-h blocking 
with 3% BSA/PBS, sections were incubated for 2 h with primary antibody (1:100 in BSA/PBS). 
The primary antibodies used were rabbit anti-CPI-17 (Woodsome et al. 2001), mouse anti-SM 
α-actin (Sigma-Aldrich Inc., Saint Louis, MO, USA), mouse anti-MYPT1 (Babco, Richmond, CA, 
USA). Mouse embryo sections were incubated for 1 h with alkaline phosphatase (AP)-
conjugated secondary antibody for rabbit or mouse IgG at 1:500 dilution. Dual color stain of 
mouse embryo section was carried out for 1 h with a mixture of the secondary antibody 
Kim et al. Histochem Cell Biol.   
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conjugated with AP (1:100) and cy5 (1:500). Rat aorta sections were stained for 1 h with a 
mixture of Cy3- and Cy5-conjugated secondary antibodies (1:500). Specimen AP was visualized 
with Vector Red AP Substrate Kit I that develop visible red color as well as red fluorescence 
(Vector laboratories Inc., Burlingame, CA, USA). Bright field color images of mouse whole 
embryo with red stain of AP substrate kit (Fig. 1) were taken using LeicaMZFLIII (Leica 
Microsystems Inc., Bannockburn, IL, USA) with a color CCD camera. Fluorescence images 
were captured using Olympus IX70 (Olympus America Inc., NY, USA) equipped with CoolSNAP 
ES2 CCD camera (Roper Sci), CARV II spinning desk confocal unit (BD Biosciences) and 
Cy3/Cy5 and GFP/Texas Red filter sets from Chroma. (Fig. 2-4). Image capturing, densitometry 
of fluorescence intensity, and digital image processing were carried out using IPLab software 
(BD Biosciences). Pseudo colors, green for SM α−actin, and red for CPI-17 and MYPT1, were 
given for all the fluorescence images. There was no noticeable auto-fluorescence under Cy3, 
Texas Red and Cy5 filters, except for the signal derived from red blood cells in arterial lumen, 
which was used as a marker to find arteries. The staining without primary antibody gave no 
detectable fluorescence signal. Representative images are shown in the figures. 3,3’-
diaminobenzidine (DAB)/Hematoxylin double stain was performed using DAB substrate kit and 
VECTOR Hematoxylin (VECTOR laboratories Inc., Burlingame, CA, USA).  Color images were 
captured using Nikon TS100 inverted microscope with Coolpix 995 digital camera. 
Kim et al. Histochem Cell Biol.   
Submitted on 11/4/08, Revised 1/7/09, 2/6/09, 3/23/09, 4/9/09 
 
9 
Statistical Analysis: Student's t-test analysis assuming an equal distribution was carried out 
using Excel software to compare to two groups. P values < 0.01 were regarded as statistically 
significant and indicated with ** in the figures. 
Kim et al. Histochem Cell Biol.   




Expression of CPI-17 in mouse embryo. Fig 1 shows immunostaining for CPI-17 (Fig. 1 A and 
B), MYPT1 (C, D), and SM α−actin (E, F) in mouse embryonic slices at E10 and 17. In E10 slice, 
CPI-17 signal (red) was exclusively detected at heart (h), intercostal muscle (ic), and neuronal 
tissues (n) (Fig. 1, panel A). The expression of CPI-17 was more prominent in E17 embryonic 
SM tissues such as aorta (a), tongue (t) esophagus (e), intestine (i) lung (lu), heart (h), as well 
as neuronal tissues (n) (Panel B). There is no significant background except for intestine in E17 
(G, H), which is probably derived from endogenous alkaline phosphatases. On the other hand, 
MYPT1 existed in all organs examined in the E10 and 17 slices, indicating the ubiquitous 
expression of MLCP (Fig. 1 C, D). Overall, the expression pattern of CPI-17 was similar to that 
of SM α−actin (E, F) and SM MHC (data not shown). However, there were significant 
differences between the expression of CPI-17 and SM α−actin at multiple loci (also see Fig. 4), 
such as neuronal tissues (n), where the expression of SM α−actin was negligible.  
 
Expression of CPI-17 in arterial SM and cardiac muscle during embryonic development. 
The expression levels of CPI-17 at embryonic heart and artery were determined by semi-
quantitative immunofluorescence (Fig. 2). SM α−actin was used as a control, because it is 
expressed at the early stage during vascular development and the expression is insensitive to 
Kim et al. Histochem Cell Biol.   
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environmental factors (Aikawa et al. 1993; Owens et al. 2004). The dual-color stain of mouse 
embryonic slices showed co-expression of CPI-17 (red) and SM α−actin (green) in arterial SM 
cells (Fig. 2A, and B) and cardiac muscle (panel C). The relative expression level of CPI-17 
appeared to be higher in the arterial SM at E14, compared to E10 (Fig. 2B). The staining 
intensity of CPI-17 varied in each artery, although it did not depend on the location or the size of 
artery. Fig. 2D shows the relative expression of CPI-17 normalized with the level of SM α−actin. 
The ratio of CPI-17 to SM α-actin doubled in arterial SM from E10 to E14 and sustained at E17. 
SM marker proteins are expressed in embryonic cardiac muscle due to the early activity of 
myocardin (Wang and Olson. 2004). Indeed, both CPI-17 and SM α−actin were detected in 
cardiac muscle at E10 and E17 (Fig. 2C). In the E10 slice, the ratio of CPI-17 expression to SM 
α−actin was 2-fold higher in heart compared to arteries. However, unlike arterial SM, the relative 
expression of CPI-17 significantly decreased from E10 to E17 (Fig. 2D).   
 
Expression of CPI-17 and MLCP in the neointimal region in an aorta injury model.  The 
neointimal formation of adult rat aorta was initiated by removing the endothelium using a wire 
catheter. Sections were subjected to immunohistochemistry with DAB/hematoxylin stain (Fig. 3 
and Supplemental figure S1). After endothelium removal SM cells outgrew from the SM layers 
between elastin sheets to the lumen, where the cells are disoriented (Fig. 3A).  The neointimal 
Kim et al. Histochem Cell Biol.   
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lesions were visible at day 7 (D7) and thickened at day 14 (D14) after the surgery (Jin et al. 
2007). The conventional immunohistochemistry showed the expression of CPI-17 at the 
neointimal lesions, whereas the signal at the neointimal cells was weaker, compared with SM 
layers (Fig. 3A left).  No signal was detected in the specimen without the primary antibody (Fig. 
3A, right).  CPI-17 stain was more prominent in the neointima, when intense color development 
was carried out (Supplemental figure S1).  Semi-quantitative dual-color immunofluorescence 
was performed to determine the expression of CPI-17 in the SM layer and the neointima (Fig. 
3B and C). As reported previously, SM α−actin was expressed in the cells at the neointima as 
well as in those at the SM layer (Fig. 3B and C, green) (Aikawa et al. 1993). The expression 
levels of CPI-17 were unchanged in SM layer of the untreated D0 control and the injured D14 
aorta (Fig. 3C, marked as SM). The ratio of CPI-17 expression to SM α−actin in the neointima 
(Fig. 3C, asterisk) declined to 30 ± 2 % of that of the SM layer at D0 and D14 (p<0.01) (Fig. 3D). 
In contrast, MYPT1 expression was not significantly different in the neointima and media (Fig. 
3E). Thus, the expression of CPI-17 is reversibly regulated in response to SM differentiation and 
de-differentiation.   
 
Expression of CPI-17 in non-arterial organs. CPI-17 was also detected in embryonic intestine, 
lung, ganglion (Fig. 4) and other tissues such as trachea and esophagus (data not shown). 
Kim et al. Histochem Cell Biol.   
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Bottom panel indicates the boxed area in the merged image. In intestine, CPI-17 was equally 
and prominently expressed in both external and internal layers of SM in the intestinal wall, 
whereas SM α−actin was present in both layers but predominantly expressed in the internal SM 
layer (Fig. 4 left). Furthermore, a significant amount of CPI-17 was detected in intestinal 
epithelium, where SM α−actin expression was negligible (Fig. 4, left, box). In the condensed 
embryonic lung, the expression of CPI-17 was prominent in most of cells including epithelial 
cells of alveoli (al) (Fig. 4, center), whereas SM α−actin was exclusively expressed in SM layers 
of artery (at), and bronchiole (arrow). The epithelial expression of CPI-17 at the alveolus was 
evident in the magnified image (Fig. 4, bottom row center).  Epithelial staining of CPI-17 was 
also observed in trachea and esophagus (data not shown). The punctate staining pattern of 
CPI-17 in Fig. 4 (right) indicates the expression in neuronal cells (n, see also boxed area lower 
row right) and precursor bone cells (b), where the expression of SM α−actin was undetectable, 
whereas arterial SM layer shows both SM α−actin and CPI-17 in the same section (Fig. 4, right, 
at, see also boxed area lower row right). No expression of SM MHC was detected in epithelium, 
neuronal or bone cells (data not shown). Thus, the expression of CPI-17 is apparently 
distinguishable from that of SM marker proteins at particular loci.  
Kim et al. Histochem Cell Biol.   




CPI-17 was up- and down-regulated in response to SM differentiation and de-
differentiation. In contrast, the expression of MYPT1 was constant at any locus and stage, unlike 
SM-type MLCK, whose promoter is controlled via a myocardin signal (Yin et al. 2006). The 
fluctuation of CPI-17 expression causes variation in the ratio of CPI-17 expression to MLCP at 
each locus. (DELETED) A lack of the expression or the phosphorylation of CPI-17 via Ca2+-
dependent PKC results in the slower force development of SM tissues (Kitazawa et al. 2004; 
Dimopoulos et al. 2007). Thus, the ratio of CPI-17 to MLCP determines the rapidity and 
magnitude of the agonist-induced SM contraction. It is known that heart rate and blood flow of 
embryo significantly increase from E10 to E14 (Keller et al. 1996). Therefore, the histological 
data suggest that the embryonic arterial SM cells increase the contractility through the 
expression of CPI-17 in response to a gain of cardiac function and an increase in blood flow. In 
contrast, CPI-17 is down-regulated in the proliferative phenotype of SM cells, such as cells at 
neointima and cultured SM cells. It is possible that mechanical stresses and/or agonist signals 
alter the signal into MLCP regulation upon the phenotype transition, and this will be a subject for 
further study. 
Immunohistochemistry detected significant levels of CPI-17 expression in the embryonic 
heart, although CPI-17 is negligible in adult rat heart (Woodsome et al. 2001). The relative 
Kim et al. Histochem Cell Biol.   
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expression of CPI-17 was decreased from E10 to E17, suggesting that CPI-17 gene becomes 
suppressed after the maturation of cardiac muscle. It is consistent with the other SM marker 
proteins whose expression is turned off in adult heart (Ruzicka and Schwartz. 1988). MYPT1 
was also detected in embryonic heart (Fig. 1C and D), suggesting that CPI-17 may be involved 
in the regulation of MLCP activity in embryonic cardiac muscle, although the roles of myosin 
phosphorylation and MLCP in embryonic heart are still unknown. In contrast, embryonic skeletal 
muscle at E10 does not express CPI-17. Wu et al reported that MYPT1 gene undergoes down-
regulation upon the differentiation of myoblasts in parallel to the up-regulation of MYPT2, a 
close member in the MYPT1 family (Wu et al. 2003). Indeed, MYPT1 is not detected in adult 
skeletal muscle (Okubo et al. 1994). The phosphorylation of myosin II is required for the 
myotube formation of myoblasts (Wu et al. 2003). Consistent with this, the expression of MYPT1 
was evident in the embryonic skeletal muscle at E10 and E17. CPI-17 seems to be unnecessary 
for the regulation of MLCP in myotube formation.   
As seen in adult animals, CPI-17 is expressed in embryonic neuronal cells.  
Furthermore, this is the first report that a significant amount of CPI-17 is detected in embryonic 
epithelial cells. The epithelial expression of CPI-17 in embryonic lung disagrees with the results 
from the adult tissue (Woodsome et al. 2001). One possibility is that the condensed embryonic 
lung emphasizes the CPI-17 staining at epithelium, compared with inflated adult lung. Indeed, a 
Kim et al. Histochem Cell Biol.   
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trace amount of CPI-17 was detected in lung epithelium from adult rats (Woodsome et al. 2001). 
The role of CPI-17 in epithelial cells is unknown. Recently, a group of tumor cells were reported 
to express a high amount of CPI-17 that causes hyper-phosphorylation of merlin/NF2 oncogene 
product and transformation of the cells (Jin et al. 2006). These tumor cells are derived from 
epithelial cells. It is possible that CPI-17 functions in the regulation of epithelial cell proliferation. 
Our findings will provide new avenues for research studying the role of CPI-17 in the regulation 
of MLCP at non-SM cells.  
The most important finding of the present study is that the expression of CPI-17 is 
reversibly regulated in arterial SM cells. It is similar to other SM marker proteins, such as SM 
myosin heavy chain, that is regulated upon the phenotype transition of SM via myocardin and 
MRTFs (Aikawa et al. 1993; Wang and Olsen 2004). However, it is unclear whether CPI-17 
expression is controlled via myocardin signal. There are significant differences in the expression 
profiles of CPI-17 and SM α−actin. Dysregulation of CPI-17 expression can cause disorders in 
the regulation of SM contraction, so that the molecular basis of the gene regulation seems to 
deserve further investigation.  
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Figure legends  
Fig. 1. Immunohistochemistry showing the presence of CPI-17, MYPT1, and SM α−actin in 
tissue sections of mouse embryos. Sagittal sections of mouse embryo at E10 and E17 were 
stained with anti-CPI-17 (A, B), MYPT1 (C, D), and SM α−actin (E, F) or without primary 
antibody as background (G, H). Red color was developed for 7 min (CPI-17) and for 6 min (SM 
α−actin and MYPT1). a, aorta; e, esophagus; h, heart; i, intestine; ic, intercostal muscle; li, liver; 
lu, lung; n, neuronal cells; t, tongue   
Fig. 2. Immunofluorescence of CPI-17 and SM α−actin in artery and heart in sagittal 
sections of mouse embryo. All the samples were stained under identical conditions including 
a 3.5-min color development. (A) Dual color Images for the presence of CPI-17 (red) and SM 
α−actin (green) in artery at E14. (B) Merged images of CPI-17 and SM α−actin in artery. The 
dots in the lumen are auto-fluorescence from red cells. (C) The expression of CPI-17 and SM 
α−actin in embryonic heart at E10 and 17. a, aorta; h, heart (D) The ratio of CPI-17 expression 
to SM α−actin in arterial SM and cardiac muscle. Mean values ± SEM were obtained from the 
staining intensity of CPI-17 normalized to that of SM α−actin at randomly-picked regions of 10 
arteries in the slice of E10, 14, 17 and 10 different spots in cardiac muscle of the E10 and 17. ** 
indicates statistical significance (p<0.01).   
Fig. 3. Expression of CPI-17, MYPT1, and SM α−actin in neointimal lesions of rat adult 
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aorta. (A) DAB/hematoxylin dual-color stain of transverse sections of aorta at 7 days after the 
surgery for denuding the endothelium.  Staining was carried out using with anti-CPI-17 and 
peroxidase-labeled secondary antibody.  Right panel shows control experiments without the 
primary antibody.   (B, C) Indirect immunohistochemistry with Cy3- and cy5-conjugated 
antibodies showing the presence of CPI-17 (B) or MYPT1 (C) in red with SM α−actin in green in 
transverse sections of aorta before (D0) and at 14 days after the surgery for denuding the 
endothelium (D14).  Asterisk indicates the neointima lesion and SM indicates smooth muscle 
layers in the media. (D, E) The relative expression level of CPI-17 (D) and MYPT1 (E).  Mean 
values ± SEM were obtained from the ratio of intensity at 20-28 different spots of SM layer and 
neointima of injured aorta.   
Fig. 4. Immunofluorescence staining for the presence of CPI-17 in non-arterial embryonic 
organs. An E17 embryo section was subjected to dual color immunofluorescence for the 
expression of CPI-17 (red) and SM α−actin (green). Confocal images focused on intestine (left), 
lung (center), and neuronal area (right) are shown. Color was developed for 7 min. Bottom 
panels show images with higher magnifications at the boxed area. SM, SM layer; epi, epithelial 
cells; *, alveolus lumen; at, artery; n, neuronal cells; b, precursor bone cells.  
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